Perrigo loses bid to revive antitrust case against AbbVie over AndroGel
Perrigo Co has lost a bid to revive a lawsuit accusing AbbVie Inc of filing a "sham" patent lawsuit to block it from launching a generic version of AbbVie''s testosterone replacement treatment AndroGel, a federal appeals court has ruled.
Perrigo loses bid to revive antitrust case against AbbVie over AndroGel
Perrigo Co has lost a bid to revive a lawsuit accusing AbbVie Inc of filing a "sham" patent lawsuit to block it from launching a generic version of AbbVie''s testosterone replacement treatment AndroGel, a federal appeals court has ruled.